





 <p><b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)</p>				ATTY. DOCKET NO.		APPLICATION NO.	
				9328-009-999		09/246,307	
				APPLICANT			
				Feder			
				FILING DATE		GROUP	
				February 8, 1999		1653	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
07		La Ferla <i>et al.</i> , "The Alzheimer's $\alpha\beta$ peptide induces neurodegeneration and apoptotic cell death in transgenic mice", <i>Nature Genetics</i> 1995, 9, 21-30					✓
		Eldadah <i>et al.</i> , "The Role of CED-3-Related Cysteine Proteases in Apoptosis of Cerebellar Granule Cells", <i>J. Neuroscience</i> 1997, 17 (16), 6105-6113					
		Su <i>et al.</i> , "Immunohistochemical evidence for apoptosis in Alzheimer's disease", <i>NeuroReport</i> 1994, 5, 2529-2533					
		Smucker, "Maximizing Function in Alzheimer's Disease: What Role for Tacrine", <i>American Family Physician</i> 1996, 645-652					
		Ott <i>et al.</i> , "Complementary and Alternative Medicines for Alzheimer's Disease", <i>J. of Geriatric Psychiatry and Neurobiology</i> 1998, 11, 163-173					
		Ruther <i>et al.</i> , "Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy", <i>J. Neural Transmission</i> 2000, 107, 815-829					
		Nalbantoglu <i>et al.</i> , "Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein", <i>Nature</i> 1997, 387, 500-505					
		Hsiao <i>et al.</i> , "Correlative Memory Deficits, $\alpha\beta$ Elevation, and Amyloid Plaques in Transgenic Mice", <i>Science</i> 1996, 274, 99-102					
		D'Hooge <i>et al.</i> , "Spatial learning deficit in mice expressing human 751-amino acid $\beta$ -amyloid precursor protein", <i>NeuroReport</i> 1996, 2807-2811					
		Graves <i>et al.</i> , "The Association between Head Trauma and Alzheimer's Disease", <i>American J. Epidemiology</i> 1990, 131(3), 491-501					
070		Plassman <i>et al.</i> , "Documented hear injury in early adulthood and risk of Alzheimer's disease and other dementias", <i>Neurology</i> 2000, 55, 1158					
EXAMINER				DATE CONSIDERED			
							
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>		<b>Atty. Docket No. (Optional)</b>  15004Z	<b>Application Number</b>  09/246,307				
		<b>Applicant(s)</b> Alan P. Kozikowski, et al.					
		<b>Filing Date</b> February 8, 1999	<b>Group Art Unit</b> 1653				
<b>U.S. PATENT DOCUMENTS</b>							
<b>EXAMINER INITIAL*</b>	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE (if appropriate)</b>	
<b>FOREIGN PATENT DOCUMENTS</b>							
	<b>REF</b>	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION</b>
							YES NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
		Massimo Falorni, et al. "Chiral Ligands Containing Heteroatoms. 11. <sup>1</sup> Optically Active 2-Hydroxymethyl Piperazines as Catalysts in the Enantioselective Addition of Diethylzinc to Benzaldehyde", <u>Tetrahedron Asymmetry</u> , Vol. 4, No. 11, pp. 2389-2398, (1993)					
		Gamini S. Jayatilake, et al., "Metabolites from an Antarctic Sponge-Associated Bacterium, <i>Pseudomonas Aeruginosa</i> ", <u>J. Nat. Prod.</u> , Vol. 59, pp. 293-296, (1996)					
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>					
		5/22/05					
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							